<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211013052759N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-20</date_registration>
      <primary_sponsor>Ilam University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the oral pregabalin and gabapentin effects as a premedication in pain control after orthopedic surgery on the upper limb.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the oral Pregabalin and Gabapentin effects as a premedication in pain control after orthopedic surgery on the upper limb.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59308</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: At the beginning, the candidates for surgery will be determined based on the entry and exit criteria, and then Balance-block randomization with 4 permutations will be used for random allocation Blocks used include: PPGG PGPG PGGP GGPP GPGP GPPG
 Where the letter P (pregabalin group) and the letter G (gabapentin group) will be. RAS (Research Analysis and Statistics) software will be used to generate random blocks and a random number table will be used to select each block. Hide created sequence To hide the created sequence, boxes will be installed that will be exactly the same and random codes will be written on them, and each code will indicate a type of drug, and the drug in the box will be exactly the same. The list of codes prepared for each drug will be determined by the research team.
Hide created sequence:
To hide the created sequence, boxes will be installed that will be exactly the same and random codes will be written on them, and each code will indicate a type of drug, and the drug in the box will be exactly the same. The list of codes prepared for each drug will be determined by the research team and the final list will be at the discretion of the lead researcher. This method will ensure that the doctor or nurse prescribing the medicine does not know the type of medicine, Blinding description: Volunteer patients will be aware of the type of both drugs to participate in the study before receiving the drug, but will not be aware of which of the two drugs they will receive in order to blind patients. Also, the nurses who collect the data will not be aware of which of the two drugs the patient has received.</study_design>
      <phase>2</phase>
      <hc_freetext>Comparison of the effect of gabapantin and oral pregabalin as a prodrug in controlling pain after orthopedic surgery on the upper limb in Imam Khomeini Hospital in Ilam..</hc_freetext>
      <i_freetext>.Intervention group: 120 patients with random entry conditions will be divided into two groups: pregabalin and gabapentin, so that there will be 60 people in each group. For the pregabalin group (P) one 150gg capsule will be prescribed one hour before surgery and for the gabapentin group 300mg will be administered two hours before the start of surgery. Patients will be given standard monitoring (blood pressure, heart rate, pulse oximetry, cardiography) at the beginning of the operating room. Patients with intravenous route No. 18 will be given 500 ml of Ringer's serum.Midazolam 1mg / kg is injected into the patient as a prodrug and at a dose of 2 mg / kg propofol and 0.5 mg / kg atracurium will be used to induce anesthesia. Will be used and after reviewing the vital signs and the appropriate depth of anesthesia, the surgeon will be allowed to begin surgery. After surgery, patients are transferred to recovery and patients are evaluated at three times (exit from recovery by anesthesiologist and at 6 and 12 hours after surgery by a nurse who is not aware of the type of medication received) for pain severity using a questionnaire. The VAS standard will be performed. In case of pain in case of pain with VAS score higher than 3, morphine will be injected intravenously at a dose of 0.1 mg / kg. The dose will be recorded in the relevant questionnaire and will continue to monitor pulse oximetry to diagnose loss of consciousness or respiratory depression in these patients, and we will even prescribe supplemental oxygen if necessary. Patients will then be evaluated for postoperative pain and the average dose of morphine in the two groups receiving pregabalin and gabapentin. Also, this comparison in gender and age subgroups and body mass index will be important for us and will be examined..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rana Roshanfekr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.201, kavand dead end, javad mosqe alley, Safa st.</address>
        <city>لرستان</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6913884343</zip>
        <telephone>+98 66 4260 8531</telephone>
        <email>Roshanfekrrana@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rana Roshanfekr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.201, kavand dead end, javad mosqe alley, safa st.</address>
        <city>Brujerd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6913884343</zip>
        <telephone>+98 66 4260 8531</telephone>
        <email>Roshanfekrrana@gmail.com</email>
        <affiliation>Ilam University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having elective orthopedic surgery on one of the upper limbs with general anesthesia
Age range 20_55 years
ASA class one and two</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient or guardian dissatisfaction with participation in the study, severe hemodynamic instability, neurological disease or mental disorders, patients with a history of seizures, acute and chronic kidney disease, patients with a history of pregabalin and gabapentin allergies, alcohol and drug abuse Or a history of chronic analgesia
Severe hemodynamic instability
Neurological disease or mental disorders
Patients with a history of seizures
Acute and chronic kidney disease
Patient with a history of pregabalin and gabapentin allergies
alcohol and drug abuse Or a history of chronic analgesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>.Intervention group: 120 patients with random entry conditions will be divided into two groups: pregabalin and gabapentin, so that there will be 60 people in each group. For the pregabalin group (P) one 150gg capsule will be prescribed one hour before surgery and for the gabapentin group 300mg will be administered two hours before the start of surgery. Patients will be given standard monitoring (blood pressure, heart rate, pulse oximetry, cardiography) at the beginning of the operating room. Patients with intravenous route No. 18 will be given 500 ml of Ringer's serum.Midazolam 1mg / kg is injected into the patient as a prodrug and at a dose of 2 mg / kg propofol and 0.5 mg / kg atracurium will be used to induce anesthesia. Will be used and after reviewing the vital signs and the appropriate depth of anesthesia, the surgeon will be allowed to begin surgery. After surgery, patients are transferred to recovery and patients are evaluated at three times (exit from recovery by anesthesiologist and at 6 and 12 hours after surgery by a nurse who is not aware of the type of medication received) for pain severity using a questionnaire. The VAS standard will be performed. In case of pain in case of pain with VAS score higher than 3, morphine will be injected intravenously at a dose of 0.1 mg / kg. The dose will be recorded in the relevant questionnaire and will continue to monitor pulse oximetry to diagnose loss of consciousness or respiratory depression in these patients, and we will even prescribe supplemental oxygen if necessary. Patients will then be evaluated for postoperative pain and the average dose of morphine in the two groups receiving pregabalin and gabapentin. Also, this comparison in gender and age subgroups and body mass index will be important for us and will be examined.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score in vas questionnaire. Timepoint: Measurement of pain intensity after recovery and 6 and 12 hours after surgery. Method of measurement: Visual analogue scale questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ilam University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-09</approval_date>
        <contact_name>Ethics Committee of Ilam University of Medical Sciences</contact_name>
        <contact_address>No. 201, Kavand dead end, Javad mosque alley, Safa st. Brujerd Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
